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Background: Interleukin-12 receptor β (IL-12Rβ2) knock-out mice 
develop lung adenocarcinoma, and epigenetic silencing by CpG meth-
ylation leads to loss of this gene in B-cell malignancies. The aim of this 
study was to determine whether IL-12Rβ2 methylation is a common 
feature in human lung cancer.
Methods: We examined mRNA expression of IL-12Rβ2 in lung cancer 
cell lines, and normal bronchial, and tracheal epithelial cells using RT-
PCR, and we examined the methylation status of IL-12Rβ2 in primary 
lung cancers.
Results: Loss of expression was found in 10 of 13 (77%) NSCLC cell 
lines, and 2 of 5 (40%) SCLC cell lines compared with normal bron-
chial or tracheal cells. Treatment of 11 expression-negative cell lines 
with a demethylating agent restored expression in all cases. Aberrant 
methylation status of IL-12Rβ2 gene was reversely concordant with its 
mRNA expression. IL-12Rβ2 methylation was detected in 96 of 230 
NSCLCs (42%) and 3 of 6 SCLCs (50%). IL-12Rβ2 rmethylation cor-
related with poorer prognosis in lung adenocarcinomas (hazard ratio = 
2.33, p = 0.0059).
Conclusions: We conclude that epigenetic silencing of IL-12Rβ2 is a 
frequent event in lung cancers. Aberrant methylation of this gene seems 
to be a useful predictor of long-term outcome for adenocarcinoma of 
the lung.
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Background: Activation of the epidermal growth factor receptor 
(EGFR) in cancer cells has been shown to promote processes involved 
in tumor cell proliferation, angiogenesis, invasion, and metastasis, and 
to inhibit apoptosis. The purpose of the present study is to verify the 
role of genetic alterations involved in the EGFR pathways in non-small 
cell lung cancer (NSCLC) development.
Methods: We analyzed mutations of the EGFR, KRAS and PIK3CA 
genes and ampliﬁcation of the loci corresponding to those genes in 
primary tumors from 96 patients with NSCLC. Mutation analyses of 
EGFR (exon 19 and 21), KRAS (exon 2 and 3), and PIK3A (exon 9 
and 20) were performed by the PCR-direct sequencing method. Gene 
ampliﬁcation analyses were performed by the ﬂuorescent in situ hy-
bridization method.
Results: EGFR, KRAS, and PIK3CA gene mutations were found in 
22 (23%), 2 (2%), and 3 (3%) of 96 NSCLCs, respectively. The copy 
number gains of these genes were 26 (27%), 10 (10%), and 19 (20%) 
of them, respectively. On the whole, 55 (57%) of the 96 NSCLCs had 
one or the other gene alterations. The gene alterations were evenly 
found in cases with early stage disease as well as in those with ad-
vanced disease. It is suggested that these gene alterations play essential 
roles in the initial step of lung carcinogenesis. EGFR gene mutations 
were preferentially detected in females (34.1%, 14/41), non-smokers 
(50.0%, 14/28), and adenocarcinomas (35.1%, 20/57), with statistical 
signiﬁcances (Chi-square test, P < 0.05), which conﬁrmed previous 
observations. In contrast, PIK3CA gene ampliﬁcation were preferen-
tially detected in males (29.1%, 16/55), smokers (34.1%, 16/51), and 
squamous cell carcinomas (41.3%, 12/29) (Chi-square test, P < 0.05). It 
is suggested that certain carcinogens in the tobacco smoke might have 
caused PIK3CA gene ampliﬁcation to promote squamous cell carci-
noma development. 
Conclusions: The pathway mediated through EGFR, KRAS and 
PIKCA gene has critical role in the development of NSCLC. NSCLCs 
can be divided into speciﬁc molecular subsets according to the genetic 
alterations in this pathway.
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Cancer is worldwide problem and lung cancer is one of the frequent 
ones causing ca 1 million deaths every year. Although early stage lung 
cancer is in most cases surgically curable, about 80% of lung cancer 
cases due to tumour spread or distant metastases need either radio-
therapy, adjuvant or neoadjuvant polychemotherapy. Despite of certain 
success achieved in the ﬁeld of combined therapy, the prolonged use of 
it is limited by developing resistance to drugs and side effects of this 
treatment.
In everyday lung cancer diagnostics histological classiﬁcation is used. 
Accordingly, lung cancer is divided to small cell lung carcinoma (20% 
of all lung cancers) and non-small cell lung carcinoma (NSCLC, 80% 
of all lung cancers) including three main groups: squamous cell carci-
noma (20-35%), giant cell carcinoma (4.5-15%) and adenocarcinoma 
(30-50%). Despite of lung cancer histological subgroup diagnostics, 
the clinical course of the same stage patients is quite different. This fact 
suggests that histological form of cancer is not sufﬁcient predictor of 
clinical course of the disease.
The cancer (120) and control samples of the current study originate 
from Tartu University Hospital and are collected from 28.11.2002 to 
31.12.2006. Tissue samples were snap frozen in liquid nitrogen during 
the operation and processed in RNAlater ICE (Ambion) to elimi-
nate RNA any degradation. RNA was extracted using RiboPure Kit 
(Ambion) which was followed by RNA quantization (Nanodrop) and 
quality control on Agilent Bioanalyzer Lab-on-a-Chip technology. RIN 
value cut-off was set to 7. 
In the current study we have used Illumina whole genome gene expres-
sion arrays of 47 000 features to monitor molecular patterns of different 
NSCLC samples in hope to ﬁnd differentially expressed genes that 
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would help us to discriminate different NSCLC types and eventually 
predict the survival and clinical course of the patients.
Our previously performed studies with these tissue samples have 
shown upregulation of well-known cancer associated genes like STEAP 
and downregulation of DAPK1, TNFSF10 and EDG1.
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Background: Asbestos is recognised by the IARC as a human lung 
carcinogen. The relationship between asbestos and tobacco in lung 
cancer causation has proven difﬁcult to deﬁne, and causal attribution 
of lung cancer in smokers who have also been exposed to asbestos 
is often difﬁcult. There are no clinical or pathological characteristics 
which distinguish lung cancers partly or wholly attributable to asbestos 
from those due to tobacco alone. The hypothesis for this study was 
that, despite their phenotypic similarity, lung cancers arising in subjects 
exposed to respirable asbestos have a different gene expression proﬁle 
from those arising in subjects with no asbestos exposure. 
Subjects and Methods: With institutional ethics committee approval 
we performed MIAME compliant microarray expression analysis on 
RNA extracted from resected tumour tissue in 37 cases of adenocar-
cinoma (AC) on the Operon Human V.2 22k platform. Lung asbestos 
ﬁbre burden was measured by tissue digestion and ﬁltration, counting 
ferruginous bodies (FB) by light microscopy. Fibre burdens >20 FB per 
gram wet weight (/gww) are usually associated with occupational or 
signiﬁcant environmental exposure to respirable asbestos (1). Tumour 
gene expression was compared between 24 subjects with 0 FB /gww 
(Group 1) and 13 subjects with >=20 FB/gww (Group 2) using Avadis 
software. Subject groups were similar for age, gender, and smoking. 
Class prediction was performed in BRB Array Tools v3.5.
Results: 
1. Volcano plots identiﬁed 21 probes with signiﬁcantly different 
expression at p=0.001 and magnitude of absolute fold change >1.5 
between these two classes, almost all upregulated in Group 2. The 
probes corresponded to one pseudogene, ten unknown genes and 
ten annotated genes including genes in the RAS pathway, novel 
zinc ﬁnger proteins and genes with redox function. The direction of 
expression difference was validated for 5 out of 6 of these genes by 
RT-PCR in an independent test set of 30 adenocarcinomas. 
2. A 95-gene classiﬁer was developed using the 1 nearest neighbour 
prediction model by leave one out cross-validation. The mean cor-
rect classiﬁcation rate was 89%, permutation p<0.002. Negative 
predictive value was 0.852 indicating potential of this classiﬁer to 
rule out adenocarcinoma related to asbestos exposure. Receiver 
operating analysis showed that the top 8 genes (by p value) could 
generate over 90% of the performance of the full classiﬁer. 
Conclusions: AC in subjects with lung asbestos bodies showed sig-
niﬁcant upregulation of several genes compared with AC in individuals 
without lung asbestos. This ﬁnding was conﬁrmed by an independent 
method in independent subjects, implicating these genes as possible 
players in asbestos carcinogenicity and / or tumour progression. A 
95-gene set was predictive of AC class based upon lung asbestos ﬁbre 
burden. The performance of an 8-gene subset requires independent 
evaluation for predictive utility as an RT-PCR panel in clinical and 
medico-legal settings. 
1.  Roggli, V. L. and L. L. Sanders (2000). Asbestos content of lung tissue and carcinoma 
of the lung: a clinicopathologic correlation and mineral ﬁbre analysis of 234 cases. Ann 
Occup Hyg 44(2): 109-17. 
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Lung cancer is a leading cause of death worldwide. Lung cancer is 
becoming the major malignancy in China. Many events including 
alterations of oncogenes and tumor suppressor genes must have oc-
curred by the time when lung cancer becomes clinically evident. We 
used the following methods including comparative genomic hybridiza-
tion; alleotyping; cDNA library construction; and DNA microarray to 
investigate human lung cancer related genes. On the basis of the above 
mentioned study, we cloned more than 50 genes, which had never been 
deeply characterized before.
We identiﬁed a novel gene highly expressed in human lung cancer 
tissue that we named OLC (overexpressed in lung cancer). Forced 
overexpression of OLC malignantly transformed NIH3T3 cells in vitro 
and in vivo. Immumohistochemistry staining indicated that OLC was 
overexpressed in human lung dysplasia/carcinoma in situ and non-
small cell lung cancer. The overexpression of OLC was also observed 
in human esophageal and laryngeal carcinoma. Small interfering RNAs 
(siRNA) mediated OLC gene silencing in two lung cancer cell lines ( 
H520, H1299) which highly expressed OLC protein, induced signiﬁ-
cant reduction of cellular growth and high rates of apoptosis. Using 
an EMSA supershift assay we demonstrated that OLC overexpression 
can induce translocation of the NF-kappaB complex (p50/p65) from 
cytoplasm to nucleus in Hela, H520, and H1299 cancer cells. Our pre-
liminary data showed a higher OLC expression in lung squamous cell 
carcinoma (SCC) of smoker patients than in lung SCC of non-smokers, 
and cigarette smoke condensate treatment increased OLC expression 
in human bronchial epithelial cells in vitro. This study indicates that 
elevation of OLC might be associated with cigarette smoking-related 
human lung carcinogenesis, particularly at early stage.
Another gene, nominated DENND2D by HGNC, from the novel gene 
pool constructed in our laboratory was investigated. DENND2D sup-
pressed the malignant transformation of NIH/3T3 cells. Transfection of 
DENND2D gene into the non-small cell lung cancer cell line, H1299, 
inhibited the cell proliferation and anchorage-independent growth in 
vitro, and reduced tumorigenicity of H1299 cell in nude mice. Flow 
cytometry assay revealed that expression of DENND2D induced G1/S-
phase arrest in the cells. Semi-quantitative reverse transcription-PCR 
demonstrated that down-regulated expression of DENND2D was ob-
served in lung cancer tissue samples, lung cancer cell lines, and the im-
mortalized human bronchial epithelial cell lines, whereas DENND2D 
remains its expression in the primarily cultured normal bronchial 
epithelial cells. The lung cancer related novel gene DENND2D may 
play important role(s) in the pathogenesis of human lung cancers. 
